SanBio Co Ltd 4592
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- ¥1,220.00
- Day Range
- ¥1,178.00–1,228.00
- 52-Week Range
- ¥380.00–1,489.00
- Bid/Ask
- ¥1,185.00 / ¥1,188.00
- Market Cap
- ¥81.40 Bil
- Volume/Avg
- 1.3 Mil / 2.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
- Website
- https://www.sanbio.com
Comparables
Valuation
|
Metric
|
4592
|
PROK
|
166480
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 51.78 | — | 17.66 |
Price/Sales | — | — | 11.63 |
Price/Cash Flow | — | — | — |
Price/Earnings
4592
PROK
166480
Financial Strength
|
Metric
|
4592
|
PROK
|
166480
|
|---|---|---|---|
Quick Ratio | 4.75 | 21.09 | 0.29 |
Current Ratio | 5.30 | 21.87 | 0.31 |
Interest Coverage | −202.54 | −15,395.90 | −7.66 |
Quick Ratio
4592
PROK
166480
Profitability
|
Metric
|
4592
|
PROK
|
166480
|
|---|---|---|---|
Return on Assets (Normalized) | −46.86% | −27.43% | −32.27% |
Return on Equity (Normalized) | −95.71% | — | −124.84% |
Return on Invested Capital (Normalized) | −73.10% | −33.56% | −45.86% |
Return on Assets
4592
PROK
166480
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wryxdzbt | Pvzlr | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hdzrxyjz | Lphml | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gkwmgmf | Jwqzyjg | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kwgwvwcj | Bszggc | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Fsdppnyfb | Kddp | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Ytqnwch | Htbx | $29.2 Bil | |||
| Moderna Inc
MRNA
| Nxmztjp | Kzj | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Mrfctmwgf | Zjrgn | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rdrqyqr | Jxdtg | $13.2 Bil | |||
| Incyte Corp
INCY
| Gqchqznm | Jdsgn | $13.0 Bil |
United States